Skip to main content
John Allan, MD, Oncology, New York, NY, New York-Presbyterian Hospital

JohnNathanAllanMD

Oncology New York, NY

Hematologic Oncology

Physician

Dr. Allan is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Allan's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital - Cornell Campus
    New York Presbyterian Hospital - Cornell CampusFellowship, Hematology/Oncology, 2012 - 2015
  • New York Presbyterian Hospital - Cornell Campus
    New York Presbyterian Hospital - Cornell CampusResidency, Internal Medicine, 2009 - 2012
  • St Louis University School of Medicine
    St Louis University School of MedicineClass of 2009

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2012 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
    Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica

Abstracts/Posters

  • Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in RichterÍs Syndrome (RS)
    John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
    John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
    John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • CD79b Expression in Richter's Transformation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Thanks. Feedback Improves Google Ads
    Thanks. Feedback Improves Google AdsSeptember 17th, 2019

Hospital Affiliations